World Journal of Pharmaceutical
and Medical Research

( An ISO 9001:2015 Certified International Journal )

An International Peer Reviewed Journal for Pharmaceutical and Medical Research and Technology
An Official Publication of Society for Advance Healthcare Research (Reg. No. : 01/01/01/31674/16)
ISSN 2455-3301
IMPACT FACTOR: 6.842

ICV : 78.6

Login Register
World Journal of Pharmaceutical and Medical Research (WJPMR) has indexed with various reputed international bodies like : Google Scholar , Index Copernicus , SOCOLAR, China , Indian Science Publications , Cosmos Impact Factor , Research Bible, Fuchu, Tokyo. JAPAN , Scientific Indexing Services (SIS) , UDLedge Science Citation Index , International Impact Factor Services , International Society for Research Activity (ISRA) Journal Impact Factor (JIF) , International Innovative Journal Impact Factor (IIJIF) , Scientific Journal Impact Factor (SJIF) , Global Impact Factor (In Process) , Digital Online Identifier-Database System (DOI-DS) , Science Library Index, Dubai, United Arab Emirates , Eurasian Scientific Journal Index (ESJI) , International Scientific Indexing, (ISI) UAE , IFSIJ Measure of Journal Quality , Web of Science Group (Under Process) , Directory of Research Journals Indexing , Scholar Article Journal Index (SAJI) , International Scientific Indexing ( ISI ) , Scope Database , Academia , 

SJIF Impact Factor: 6.842

Abstract

GYNAECOMASTIA IN PATIENTS RECEIVING TLE AND ZLN REGIMENS

Gundramy Reddy Sravani*, D. Sravani, P. Kali Prasanna, M. Rameela and T. S. Durga Prasad

ABSTRACT

Gynaecomastia is being palpated clinically when glandular tissue exceeds 0.5cm. The glandular tissue is usually soft, elastic or firm, over a period tissue becomes more fibrous, denser and hard. Gynaecomastia can occur due to many reasons like drug induced, liver cirrhosis, chronic kidney failure, hyperthyroidism, testicular or adrenal tumors and imbalance between androgen and estrogen. In our study drug induced was found to be the main cause for the occurrence of Gynaecomastia as patients does not fall under other category. This is a case study representing two patients with Gynaecomastia one receiving TLE (Tenofovir 300mg + Lamivudine 300mg + Efavirenz 600mg) and other receiving ZLN (Zidovudine 300mg + Lamivudine 150mg + Nevirapine 200mg). Diagnosis of Gynaecomastia is difficult, but based on research articles and rechallenge drug involved in the Gynaecomastia was found. Gynaecomastia is being treated by use of Tamoxifen 20mg for 3 months in case-1 and withdrawal of regimen in case-2.

[Full Text Article]    [Download Certificate]

Powered By WJPMR | All Right Reserved

WJPMR